Literature DB >> 10234590

A review of potential cardiovascular uses of intravenous glucagon administration.

C M White1.   

Abstract

Glucagon is a counter-regulatory hormone that is classically used to treat hypoglycemia. However, it can elicit the generation of cAMP within the myocardium to cause positive inotropic and chronotropic effects without the need for beta-1 adrenoceptor stimulation. Glucagon has been used extensively to treat beta-blocker overdose and has evidence for use in verapamil and imipramine overdose as well. Glucagon has been used as adjunctive therapy in shock situations and heart failure but is inferior to catecholamines. An interesting potential indication for glucagon is in treating postcountershock asystole.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10234590

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

Authors:  L N Axelsen; W Keung; H D Pedersen; E Meier; D Riber; A L Kjølbye; J S Petersen; S D Proctor; N-H Holstein-Rathlou; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  The alpha-cell as target for type 2 diabetes therapy.

Authors:  Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Treatment of Aluminium Phosphide Poisoning with a Combination of Intravenous Glucagon, Digoxin and Antioxidant Agents.

Authors:  Zohreh Oghabian; Omid Mehrpour
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

4.  Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium.

Authors:  Maria Jesús Juan-Fita; Maria Luisa Vargas; Alberto J Kaumann; Jesus Hernández Cascales
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-25       Impact factor: 3.000

5.  Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.

Authors:  Jizu Yi; David Warunek; David Craft
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 6.  Interplay Between Systemic Metabolic Cues and Autonomic Output: Connecting Cardiometabolic Function and Parasympathetic Circuits.

Authors:  Liliana Espinoza; Stephanie Fedorchak; Carie R Boychuk
Journal:  Front Physiol       Date:  2021-03-11       Impact factor: 4.566

7.  Glucagon Increases Beating Rate but Not Contractility in Rat Right Atrium. Comparison with Isoproterenol.

Authors:  Beatriz Merino; Ivan Quesada; Jesús Hernández-Cascales
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

8.  Glucagon effects on 3H-histamine uptake by the isolated guinea-pig heart during anaphylaxis.

Authors:  Mirko Rosic; Oberdan Parodi; Vladimir Jakovljevic; Maja Colic; Vladimir Zivkovic; Vuk Jokovic; Suzana Pantovic
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

9.  Does glucagon have a positive inotropic effect in the human heart?

Authors:  Jesus Hernández-Cascales
Journal:  Cardiovasc Diabetol       Date:  2018-11-27       Impact factor: 9.951

Review 10.  Pharmacological Benefits and Risk of Using Hormones in Organ Perfusion and Preservation Solutions in the Aspect of Minimizing Hepatic Ischemia-Reperfusion Injury during Storage.

Authors:  Aneta Ostróżka-Cieślik; Barbara Dolińska
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.